Clinical trials
Peanut Allergy clinical trials
Below are recruiting peanut allergy clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06260956Recruiting
Peanut and egg study for expecting mothers
This study looks at whether eating or avoiding peanuts and eggs during pregnancy can affect the baby's risk of allergies. You and your baby will be followed for a year after birth.
Rochester, New YorkAges 1 day+ - NCT07580898RecruitingPhase 1
Testing MOON101 Safety for Peanut Allergy Treatment
This study tests whether a new drug called MOON101 is safe for people with peanut allergies. The goal is to see if it might help your immune system tolerate peanuts better and reduce severe allergic reactions.
Little Rock, ArkansasAges 4–55 - NCT05695261RecruitingPhase 2
Oral microbiome capsules for peanut allergy in teens
This Phase 2 study tests whether taking capsules made from donor gut microbes is safe and can reduce allergic reactions to peanuts. It involves peanut allergy testing and close follow-up with stool samples and check-ins.
Boston, MassachusettsAges 12–17 - NCT07287033RecruitingPhase 1
Safety study of MY006 in healthy people and people with peanut allergy
This early-phase study tests a new investigational medication (MY006) to see if it is safe and how the body processes it. It is given to both healthy volunteers and people with peanut allergy. The goal is to gather safety information before larger trials.
Colorado Springs, ColoradoAges 12–55 - NCT07349212RecruitingPhase 1/Phase 2
Study of UKK-0018 for peanut allergy treatment
This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.
Camperdown, New South WalesAges 18–55 - NCT07359183Recruiting
Long-term follow-up of kids who had oral immunotherapy for allergies
This study checks on children and young people 5 to 15 years after they finished an 18-month oral immunotherapy treatment for peanut, egg, or milk allergy. It helps researchers understand how their allergies and health are doing over the long term.
Parkville, VictoriaAges Any age - NCT02192866Recruiting
Blood samples to study peanut and tree nut allergies
This study collects blood (or uses already-collected blood) to learn why peanut, tree nut, and related food allergies happen and how they behave during challenges. It may help researchers better understand allergies and improve future care.
Denver, ColoradoAges 1–75 - NCT07592780Recruiting
Building Tolerance to Peanuts in Children and Teens
This study tests whether a treatment program can help children and teenagers with peanut allergies develop tolerance to peanuts over time. The goal is to reduce the risk of serious allergic reactions if they accidentally eat peanuts.
Hong KongAges 2–17 - NCT02497261Enrolling by invitation
Study factors that predict peanut allergy at age five
This study looks at which early test results and symptoms help predict whether a child will still have a peanut allergy by age 5. It may help families and doctors better understand who is at higher risk and plan next steps.
Ages 4–10 - NCT06192914Recruiting
EPAP: A follow-up survey for severe food allergies
This study is a follow-up survey for people who have had a severe allergic reaction (anaphylaxis) to certain foods and are already in a larger allergy registry. By answering questions online, you can help researchers understand more about living with food allergies.
Berlin, State of BerlinAges Any age - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Little Rock, ArkansasAges 12–55 - NCT03835767RecruitingPhase 2
Predicting food allergy from blood IgE levels in eczema patients
This study looks for blood test patterns that may predict whether a child with eczema (atopic dermatitis) is likely to have a food allergy. If you join, you may do supervised oral food challenges with a placebo and the suspected foods to see what triggers symptoms.
Bethesda, MarylandAges 3–21 - NCT06256146Recruiting
Treating food allergies with modified oral immunotherapy
This study tests a new approach to oral immunotherapy for food allergies, aiming to make it safer and more effective. It's for people who have had a clear allergic reaction to a food and have a positive allergy test.
Montreal, QuebecAges 2–40 - NCT03936998RecruitingPhase 1/Phase 2
Study drug for peanut allergy to change immune response
This early-phase study tests VE416, a treatment meant to help reduce peanut allergy reactions by changing how the immune system responds. If you have documented peanut allergy, you may receive the study medicine and, for some people, take part in a supervised peanut “entry challenge.”
Boston, MassachusettsAges 12–55 - NCT05667610Recruiting
Immune and gut diet study for peanut-allergic children
This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.
AmsterdamAges 3–17 - NCT04163562RecruitingPhase 1/Phase 2
Oral peanut treatment trial for people with peanut allergy
This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.
Pamplona, NavarreAges 12–65 - NCT07117669RecruitingPhase 1/Phase 2
Testing a new peanut allergy treatment (ENP-501)
This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.
Aurora, ColoradoAges 14–50 - NCT07701954RecruitingPhase 1
Testing a new drug for people with allergies and high IgE
This early-phase trial tests a new medication, LCA-0061, in healthy people with high IgE levels (a sign of allergies). Part B specifically includes those with a peanut allergy. The study aims to see how safe the drug is and how the body processes it.
Mississauga, OntarioAges 18–55
Hear when a new Peanut Allergy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Peanut Allergy trials by city
Studies with a site in or near these metro areas.
Peanut Allergy trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for peanut allergy?
- Yes. Clin2 currently lists 18 recruiting peanut allergy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peanut allergy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peanut allergy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.